Briumvi

Medicinal product

(Invented) name

Briumvi

Active substance (s)

Ublituksimabas

Strength

150 mg

Pharmaceutical form

koncentratas infuziniam tirpalui

Route (s) of administration

leisti į veną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L04AG14, ublituximab

Marketing authorisation holder

Neuraxpharm Pharmaceuticals, S.L., Ispanija

Date of authorisation

2023-05-31

Date of renewal

Documents

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Concentrate for solution for infusion	6 ml
Ublituksimabas	150 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
111100	97211	1097211	flakonas	6 ml N1		Receptinis	EU/1/23/1730/001	Netiekiama	-	-	No	-	-
113010	99128	1099128	flakonas	6 ml N3		Receptinis	EU/1/23/1730/002	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2023-05-31	Registruotas